Spero jumps on positive update for UTI drug after FDA meeting

Spero Therapeutics

06/09/2022 16:21

** Shares of Spero Therapeutics Inc  SPRO.O  rise ~30% to
$0.94 - set for their biggest daily pct gain in nearly two years
    ** Co says after a U.S. FDA meeting it is aligned with the
regulator regarding resubmission of marketing application for
its experimental drug tebipenem HBr for complicated urinary
tract infection (UTI)  urn:newsml:reuters.com:*:nGNX73H0PZ  
    ** Says FDA indicated that results from an additional
late-stage trial of the drug could be sufficient to support the
approval
    ** Adds that co and FDA have also aligned on some key points
of a proposed late-stage trial design which may be the subject
of a special request, to be confirmed after protocol is
finalized
    ** In June, FDA had declined to approve the drug citing that
data from a prior late-stage trial was insufficient
    ** Including session's gain, stock down ~94% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))